Some of you may have seen this news already, but just in case. A trial has been started testing a potential new myeloma therapy that hasn't received much attention thus far.
The drug is known as CB-5083, and it's being described as the first drug in a class of therapies that inhibit an enzyme known as p97.
You can view a press release about the new trial here:
"Cleave Biosciences Initiates Phase 1 Clinical Trial Of CB-5083 In Patients With Multiple Myeloma," Cleave Biosciences press release, September 4, 2014.
The Cleave Biosciences website has additional information about CB-5083 that is relatively technical, but may interest some of our readers:
"CB-5083 is a potent, highly selective, oral p97 inhibitor with broad in vivo activity in both multiple myeloma and solid tumor xenografts. CB-5083 is a potent inhibitor of endoplasmic reticulum associated degradation and induces a lethal unfodled protein response. Multiple myeloma is a cancer with a well-known dependence on protein homeostasis for survival with the proteasome inhibitors bortezomib and carfilzomib as FDA approved drugs. These agents are not effective in solid tumors owing to both chemistry and pharmacology limitations. Not only has Cleave demonstrated activity in solid tumors with CB-5083, we have also identified molecular features that correlate to increased anti-tumor activity in preclinical models."
For those who are really technically minded, the Cleave website also has a detailed (and quite technical) description of p97 and its potential value as a target in anti-cancer therapy.
|
||
Independent, up-to-date news and information for the multiple myeloma community. |
|
